Time to stable disease, progressive disease, and death. NSCLC: non–small cell lung cancer; PD: progressive disease; SD: stable disease. Note: Time to stable disease, progression, and death of all patients treated with Helixor-M (N = 21). The treatment duration is shown as the length of bars. The numbers in the parentheses are the number of prior systemic therapies (including targeted therapy, hormonal therapy, immunotherapy, or chemotherapy), the number of prior radiation treatments, and the number of surgeries. The time to death should be interpreted with caution, as patients received different subsequent treatments.